Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 35 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

1 - 12 of 35

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 35 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Major Depressive Disorder Clinical Study

Recruiting

Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.

Conditions:

Major Depressive Disorder

Major Depression

Major Depressive Episode

Major Depressive Disorder (MDD)

Major Depressive Disorders

Learn More

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants with Diffuse Large B-Cell Lymphoma

NCT03656835

Recruiting

This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[ILN\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. It is not yet known how well ILN biochip-based testing monitors treatment response or detects relapse in participants with diffuse... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma

Learn More ›

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495

Recruiting

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunother... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/21/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +1 locations

Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Learn More ›

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients with Diffuse Large B-Cell Lymphoma

NCT06031194

Recruiting

This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/02/2025

Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma

Learn More ›

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Recruiting

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

03/21/2025

Locations: Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut +36 locations

Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa

Children's Mercy Hospital ( Site 1024), Kansas City, Missouri

Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey

New York Medical College ( Site 1023), Valhalla, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota

Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota

University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah

Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales

Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana

Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site, São José do Rio Preto, Sao Paulo

Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso

Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 14, Copenhagen, Hovedstaden

Gustave Roussy ( Site 1103), Villejuif, Ile-de-France

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 11, Nantes, Pays-de-la-Loire

CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes

Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Sit, Münster, Nordrhein-Westfalen

Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set

Sheba Medical Center ( Site 1675), Ramat Gan, Not set

Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set

Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set

Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona

Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set

Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital ( Site 1983), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set

Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set

Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England

University College London Hospital ( Site 1350), London, London, City Of

University Hospital of Wales ( Site 1346), Cardiff, Not set

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +83 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site, Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( S, Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Si, Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine (, Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co, Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Recruiting

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: Cotton O'Neil Cancer Center ( Site 0108), Topeka, Kansas +35 locations

Cotton O'Neil Cancer Center ( Site 0108), Topeka, Kansas

Truman Medical Center ( Site 0122), Kansas City, Missouri

OptumCare Cancer Care ( Site 0121), Las Vegas, Nevada

Comprehensive Cancer Centers of Nevada ( Site 0113), Las Vegas, Nevada

New York Oncology Hematology, P.C. ( Site 0129), Albany, New York

Blue Ridge Cancer Care ( Site 0132), Roanoke, Virginia

Instituto de Investigaciones Clinicas Mar del Plata ( Site 0306), Mar del Plata., Buenos Aires

Fundacion Estudios Clinicos ( Site 0311), Rosario., Santa Fe

Beijing Cancer Hospital ( Site 3101), Beijing, Beijing

Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123), Nanning, Guangxi

MEDI-K ( Site 0701), Guatemala, Not set

Cen Integral Onco Gastro y Hemato Onco Guatemala S.A. ( Site 0703), Guatemala, Not set

Queen Mary Hospital ( Site 3201), Hong Kong, Not set

Carmel Hospital ( Site 1903), Haifa, Not set

Hadassah Medical Center ( Site 1901), Jerusalem, Not set

Sourasky Medical Center ( Site 1904), Tel Aviv, Not set

Poria Medical Center ( Site 1902), Tiberias, Not set

Kobe City Medical Center General Hospital ( Site 3318), Kobe, Hyogo

Saitama Medical University Hospital ( Site 3305), Iruma-gun, Saitama

Kyushu University Hospital ( Site 3313), Fukuoka, Not set

University Hospital,Kyoto Prefectural University of Medicine ( Site 3315), Kyoto, Not set

University of Miyazaki Hospital ( Site 3319), Miyazaki, Not set

Okayama University Hospital ( Site 3311), Okayama, Not set

Yamagata University Hospital ( Site 3312), Yamagata, Not set

Pusan National University Hospital ( Site 3804), Busan, Pusan-Kwangyokshi

Severance Hospital, Yonsei University Health System ( Site 3802), Seoul, Not set

Samsung Medical Center ( Site 3807), Seoul, Not set

BRCR Global - Mayaguez ( Site 1003), Mayaguez, Not set

Auxilio Mutuo Cancer Center ( Site 1001), San Juan, Not set

Ospedale Regionale Bellinzona e Valli ( Site 2701), Bellinzona, Ticino

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( S, Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Si, Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903), Lviv, Lvivska Oblast

SNPE National Cancer Institute ( Site 2902), Kyiv, Not set

Universal Clinic Oberig ( Site 2908), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co, Kyiv, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06806033

Recruiting

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/21/2025

Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +7 locations

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT03223610

Recruiting

Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/19/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma

Learn More ›

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

NCT06249191

Recruiting

This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the bo... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

03/19/2025

Locations: OHSU Knight Cancer Institute, Portland, Oregon

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma

Learn More ›

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028

Recruiting

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: University of California Los Angeles /ID# 246357, Los Angeles, California +31 locations

University of California Los Angeles /ID# 246357, Los Angeles, California

Yale University School of Medicine /ID# 259081, New Haven, Connecticut

Mount Sinai Medical Center-Miami Beach /ID# 248251, Miami Beach, Florida

Fort Wayne Medical Oncology and Hematology, Inc /ID# 250113, Fort Wayne, Indiana

Indiana University Melvin and Bren Simon Comprehensive Cancer Center /ID# 259872, Indianapolis, Indiana

Tulane Cancer Center Clinic /ID# 249586, New Orleans, Louisiana

START Midwest /ID# 252359, Grand Rapids, Michigan

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 245459, New York, New York

Levine Cancer Institute /ID# 246363, Charlotte, North Carolina

University Of Cincinnati Medical Center /ID# 262288, Cincinnati, Ohio

University of Texas MD Anderson Cancer Center /ID# 245463, Houston, Texas

University of Utah Health Hospital /ID# 259924, Salt Lake City, Utah

Northwest Medical Specialties - Tacoma /ID# 260376, Tacoma, Washington

Monash University /ID# 246366, Clayton, Victoria

The Alfred Hospital /ID# 248592, Melbourne, Victoria

UZ Gent /ID# 246462, Gent, Oost-Vlaanderen

Universitair Ziekenhuis Leuven /ID# 246461, Leuven, Vlaams-Brabant

CHRU Lille - Hopital Claude Huriez /ID# 252054, Lille, Nord

IUCT Oncopole /ID# 259409, Toulouse Cedex 9, Occitanie

Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 252062, Berlin, Not set

Shamir Medical Center /ID# 257711, Beer Ya'akov, HaMerkaz

The Chaim Sheba Medical Center /ID# 251442, Ramat Gan, Tel-Aviv

Hadassah Medical Center-Hebrew University /ID# 251441, Jerusalem, Yerushalayim

Rabin Medical Center /ID# 257665, Petah Tikva, Not set

Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 246537, L'Hospitalet de Llobregat, Barcelona

Hospital Universitario Vall d'Hebron /ID# 245475, Barcelona, Not set

Hospital Clinic de Barcelona /ID# 246543, Barcelona, Not set

Hospital Universitario Ramon y Cajal /ID# 246540, Madrid, Not set

Hospital Universitario 12 de Octubre /ID# 246538, Madrid, Not set

Leeds Teaching Hospitals NHS Trust /ID# 245470, Leeds, West Yorkshire

The Royal Marsden NHS Foundation Trust /ID# 250324, London, Not set

The Christie Hospital /ID# 250325, Manchester, Not set

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma

Learn More ›

Vaccine Responses in Patient with Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

NCT06784167

Recruiting

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/17/2025

Locations: OHSU Knight Cancer Institute, Portland, Oregon

Conditions: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Primary Mediastinal Large B-Cell Lymphoma, Small Lymphocytic Lymphoma

Learn More ›

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT04739813

Recruiting

Background: Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. Indolent B-cell lymphomas are generally incurable with standard therapy and treatment is aimed at controlling symptoms and achieving a durable remissions. Researchers want to see if a combination of drugs can help patients with both aggressive and indolent B-cell lymphomas. Objective: To learn if it is safe and effectiv... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

03/12/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma

Learn More ›

1 - 12 of 35